Covidien shares should be bought on pullbacks, says RBC Capital RBC Capital believes that Covidien's operating margin will bottom in FY14. The firm thinks the company's EPS growth can reach 10% or more in the near-term, but it believes this outlook is already reflected in the stock's valuation. It keeps a Sector Perform rating on the stock.
News For COV From The Last 14 Days
Check below for free stories on COV the last two weeks.
Covidien sees long-term double digit EPS growth Other long term goals include: Mid-single digit sales growth, returning cash to shareholders, leveraging cash flow for long-term profitable growth. Comments from slides that were presented at the Raymond James Institutional Investors Conference.
Covidien announces CE Mark approval for Puritan Bennett 980 ventilator Covidien announced its Puritan Bennett 980 ventilator has received European Economic Area CE Mark approval. The Puritan Bennett 980 ventilator system is for patients ranging from neonatal to adult. The ventilator system was also approved for commercial distribution in the U.S., Japan and Canada and will be available for sale in those countries as well as the EEA in the coming months.